Physician profile
Michael W Early
NPI 1376613570
$4,147.68
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $1,075 · 2021: $540 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $917.46 | 2019-2021 | |
| Pfizer INC. | $543.56 | 2019-2021 | |
| Novo Nordisk INC | $449.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $293.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $291.65 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $217.31 | 2019-2020 | |
| Amarin Pharma, INC. | $170.01 | 2019-2020 | |
| Astellas Pharma US INC | $163.96 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $156.66 | 2019-2021 | |
| Melinta Therapeutics, LLC | $124.05 | 2019 | |
| Amgen INC. | $123.90 | 2019 | |
| Medtronic USA, INC. | $102.70 | 2020 | |
| Lilly USA, LLC | $96.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $34.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.28 | 2021 | |
| Horizon Therapeutics Plc | $19.64 | 2020 | |
| Phadia US INC. | $16.94 | 2020 | |
| Medline Industries LP | $12.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.